New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
|Articles|February 1, 2020
- BioPharm International-02-01-2020
- Volume 33
- Issue 2
BioPharm International, February 2020 Issue (PDF)
Click the title above to open the BioPharm International February 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Managing Risk for Cell and Gene Therapy Logisticsover 6 years ago
The Call for a Rapid Responseover 6 years ago
Data Management Practicesover 6 years ago
Biopharma Analysis Benefits from New Technology and Methodsover 6 years ago
Cell Therapies: The Living End of Growth Opportunitiesover 6 years ago
Fresh Thinking in Biologic Drug Formulationover 6 years ago
Cell Culture Variables for Gene Therapy Vectorsover 6 years ago
Challenges in Vector Purification for Gene TherapyAdvertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
Advertisement
Advertisement